Large gap with delayed quotes
Analysis date: 18.09.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 11.08.2026.
Quality
Weak
Weak
Two stars since 08.09.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 11.08.2026 at a price of 24.34.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 08.09.2026.
4wk Rel Perf
7.39%
7.39%
The four-week dividend-adjusted overperformance versus STOXX600 is 7.39%.
Risk
Middle
Middle
Moderate, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.86%.
Mkt Cap in $bn
1.89
1.89
With a market capitalization <$2bn, LAKEFRONT BIOTHERAPEUTICS is considered a small-cap stock.
G/PE Ratio
-1.16
-1.16
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-10.56
-10.56
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-12.30%
-12.30%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
8
8
Over the last seven weeks, an average of 8 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
82
82
For 1% of index variation, the stock varies on average by 0.82%.
Correlation
0.38
0.38
Stock movements are strongly independent of index variations.
Value at Risk
3.66
3.66
The value at risk is estimated at EUR 3.66. The risk is therefore 14.66%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
10.10.2012
10.10.2012